Introduction
The G1691A mutation of coagulation factor V (factor V Leiden, FVL) and the G20210A mutation of the prothrombin gene (prothrombin mutation) represent the most common hereditary risk factors for venous thrombosis. According to population-based epidemiologic studies, carriers of the heterozygous FVL or prothrombin mutation have an approximately 5-fold or 2-fold increase, respectively, in the relative risk for the manifestation of venous thrombosis. 1 In Factor V Leiden (FVL) mutation and prothrombin G20210A mutation are common hereditary risk factors for venous thrombosis. In the current study, 40 patients (mean age ± standard deviation, 35 ± 11 years) and 764 healthy control subjects (mean age ± standard deviation, 37 ± 14 years) were enrolled to assess the potential role of these mutations in the manifestation of thrombotic microangiopathies. Compared with controls, neither the heterozygous FVL mutation (7.5% vs 8.5%; P = 1) nor the heterozygous prothrombin mutation (2.5% vs 2.8%; P = 1) was more prevalent in the patients. The findings do not support a significant role of FVL and prothrombin mutations as risk factors for the manifestation of thrombotic microangiopathies. Thus, screening for these mutations does not allow the identification of individuals at increased risk for these rare thrombotic disorders. Keywords: thrombotic microangiopathies; factor V Leiden mutation; prothrombin mutation forms (TTP-HUS) are distinguished. 6, 7 Although a defect in the von Willebrand factor cleaving protease ADAMTS 13 (a disintegrin-like and metalloprotease with thrombospondin-1 motif) or a deficiency of complement regulatory factors, such as factors H and I, has been reported in patients with thrombotic microangiopathies, the pathogenesis remains unclear in the majority of patients. 8 In this study, we evaluated the potential role of FVL and prothrombin mutations for the onset of thrombotic microangiopathies. According to our results, both mutations do not contribute significantly to the onset of these rare thrombotic disorders.
Patients and Methods

Patients and Controls
From January 2003 until March 2006, 40 patients (mean age ± standard deviation, 35 ± 11 years; range, 19-66 years; 32 females and 8 males) admitted with the diagnosis of thrombotic microangiopathy were enrolled in the study. All patients were residents of Northrhine-Westfalia, Germany, and of Caucasian origin.
Diagnosis was based on established clinical criteria, in particular (a) schistocytic-hemolytic anemia (hemoglobin <12 g/dL), (b) platelet count <100 000/μL, and (c) organ dysfunction without alternative explanation. 6, 7 Additional laboratory parameters such as deficiency of the von Willebrand factor cleaving protease ADAMTS 13 or an elevation of the lactate dehydrogenase were not employed as diagnostic criteria. According to the pattern of organ involvement, HUS with isolated renal dysfunction, TTP with isolated neurological deficits, and TTP-HUS with both renal dysfunction and neurological deficits were distinguished. According to this classification schedule, 18 patients had HUS, 9 TTP, and 13 TTP-HUS. The mean number of episodes at inclusion was 1.75 ± 1.45 (range 1-6). The activity of the von Willebrand factor cleaving protease was available for 23/40 patients (57.5%) and was normal (>20% of normal) in all cases.
As controls, a total of 764 healthy control subjects (mean age ±standard deviation, 37 ± 14 years; range, 13-93 years; 435 females and 329 males) were recruited. These subjects were from the same geographical region as the patients, but unrelated to them. All controls were Caucasian. The study was performed according to the Helsinki declaration, and informed consent was obtained.
Laboratory Analysis
Genomic DNA was extracted from peripheral blood leukocytes using the Chelex system (BioRad, München, Germany) or the Qiagen system (Qiagen, Hilden, Germany). Genotyping according to standard procedures was performed to assess the presence of the G1691A mutation of the FVL and the G20210A mutation of the prothrombin gene using a polymerase chain reaction employing the LightCycler technique. [9] [10] [11] 
Statistical Analysis
From the prevalences of the FVL and prothrombin mutations in patients and healthy control subjects, relative manifestation risks were calculated and expressed as odds ratios (OR). Differences in proportions were tested by the Fisher's exact test. Statistical significance was assumed at a P value below .05. Confidence intervals (CIs) were calculated at the 95% level. To rule out an influence of inhomogeneous composition of the patient and control group on the results, a multiple logistic regression procedure was performed to adjust relative risks (ORs) and CIs for age and gender. All statistical analyses were performed with the SAS software (version 8.2; SAS Institute Inc, Cary, NC).
Results
G1691A Mutation of the Factor V Gene (Factor V Leiden)
None of the patients suffering from thrombotic microangiopathy who were enrolled in the study was a carrier of the homozygous G1691A mutation of FVL. The heterozygous FVL mutation was present in 3 out of 40 patients (7.5%) and 65 out of 764 control subjects (8.5%). The differences in the frequency of the FVL mutation in patients and controls were not statistically significant. From the genotype prevalences, a relative risk (OR) of 0.87 (95% CI, 0.2-2.9; P = 1) for the manifestation of thrombotic microangiopathies was calculated for patients carrying the heterozygous FVL mutation. After adjustment for gender and age, the OR was 0.8 (95% CI, 0.2-2.7; P = .71). Thus, our data do not support a relevant role of the heterozygous FVL mutation for the manifestation of thrombotic microangiopathies (Table 1) .
Interestingly, the 3 patients carrying the heterozygous FVL mutation shared the TTP-HUS subtype of thrombotic microangiopathies, whereas the mutation was not present in patients classified as TTP or HUS. Although not statistically significant, analysis of TTP-HUS patients provided evidence for an increased manifestation risk in carriers of the heterozygous FVL mutation (adjusted OR, 2.92; 95% CI, 0.8-11; P = .11).
G20210A Mutation of the Prothrombin Gene
None of enrolled patients carried the homozygous G20210A mutation of the prothrombin gene. The prevalence of the heterozygous prothrombin mutation between patients (2.5%) and controls (2.8%) did not differ significantly. From the genotype prevalences, a relative risk (OR) of 0.86 (95% CI, 0.1-6.6; P = 1) for the manifestation of thrombotic microangiopathies was calculated for patients carrying the heterozygous prothrombin mutation. After adjustment for gender and age, the OR was 0.94 (95% CI, 0.2-2.7; P = .95). Thus, the calculated relative risk did not reveal a relevant contributory effect of the heterozygous prothrombin mutation for the manifestation of thrombotic microangiopathies ( Table 1) .
The only patient carrying the heterozygous prothrombin mutation suffered from TTP-HUS. Although not statistically significant, analysis for this subgroup resulted in an increased manifestation risk (adjusted OR, 3.06; 95% CI, 0.4-25.2; P = .3).
Discussion
In this study, we examined the potential role of the G1691A mutation of the factor V gene and the G20210A mutation of the prothrombin gene for the manifestation of thrombotic microangiopathies. Comparing the genotype prevalences in patients and healthy control subjects, our data do not support a significant contribution of both mutations on the manifestation of these rare thrombotic disorders.
Because carriers of the heterozygous G1691A mutation of the factor V gene and the heterozygous G20210A mutation of the prothrombin gene among the patients were restricted to those suffering from the clinically intermediate form of thrombotic microangiopathies (TTP-HUS), a potential role of both mutations in this subgroup of patients cannot be excluded. However, larger patient cohorts are required to clarify this issue.
Although no data regarding the role of the prothrombin mutation in the context of thrombotic microangiopathies have been published, 2 studies addressed the role of the heterozygous G1691A mutation in this setting. In HUS patients with normal ADAMTS 13 activity, Krieg et al 12 found an increased prevalence of the factor V Leiden mutation, suggesting an association of this genetic defect with an increased manifestation risk. Raife et al 13 reported on a significantly increased manifestation risk of thrombotic microangiopathies in subgroups of patients carrying the heterozygous G1691A mutation of the factor V gene with normal ADAMTS 13 activity, but not in other patient groups. The apparent conflict with our data is most likely explained by different diagnostic criteria employed for the diagnosis of thrombotic microangiopathies, the classification of disease, and, consequently, to the recruitment of patients for clinical studies. We employed strict criteria, necessarily requiring the presence of characteristic clinical symptoms, particularly neurological deficits and/or renal dysfunction. Although we could only recruit a comparably low number of patients in a single-center approach using these strict criteria, all patients enrolled in our study had clinically relevant disease that was potentially life-threatening and required plasma therapy. 6, 7 Thus, our selection criteria could have excluded mild forms of disease that fulfill the laboratory criteria of thrombotic microangiopathies (microangiopathic hemolytic anemia, low platelet count, and elevated lactate dehydrogenase levels), but do not exhibit life-threatening clinical manifestations. Altogether, selection of different patients for studies of thrombotic microangiopathy might be highly variable, which, consequently, could have significant influence on the results of association studies. The pathogenetic effect of both G1691A mutation of the factor V gene (FVL) and the G20210 mutation of the prothrombin gene in the pathogenesis of venous thrombosis is well established. 1 The FVL mutation slows down the proteolytic inactivation of factor Va by activated protein C, which, in turn, leads to the increased generation of thrombin. The promoter mutation G20210A of the prothrombin gene is associated with elevated plasma levels of factor II (prothrombin). The clinical relevance of both FVL mutation and prothrombin mutation in the pathogenesis of venous thromboembolism is reflected by a significantly higher prevalence of these mutations among patients with a history of thrombosis compared with healthy control subjects. 1 In contrast to venous thrombosis, the prothrombotic effect of the FVL and the prothrombin mutations is questionable in arterial thrombotic complications. [2] [3] [4] [5] This observation can be explained by an inferior role of fibrin formation in arterial thrombogenesis, because platelets are more relevant at high-shear stress conditions. Because the thrombotic events are preferentially localized in the arterial microvasculature in thrombotic microangiopathies, the inferior relevance of FVL and prothrombin mutations in this setting is compatible with results obtained in other arterial thromboses, such as myocardial infarction and ischemic stroke. [2] [3] [4] [5] As is the case in thrombotic microangiopathies, these mutations appear to be restricted to well-defined subgroups of patients in the context of arterial thrombosis.
In summary, our study does not support a contributory effect of the FVL and the prothrombin mutations in the pathogenesis of thrombotic microangiopathies, particularly cases with normal ADAMTS 13 activity. Comparable with other thrombotic events localized in the arterial vasculature, both mutations might only be relevant in a small subset of clinically affected patients. Because of the low prevalence of disease, multicenter trials are needed to further clarify this issue.
